Advertisement

Topics

Companies Related to "Aplidin - Dexamethasone in Relapsed/Refractory Myeloma" [Most Relevant Company Matches] RSS

21:23 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Aplidin - Dexamethasone in Relapsed/Refractory Myeloma" found in our extensive corporate database of over 50,000 company records.

Showing "Aplidin Dexamethasone Relapsed Refractory Myeloma" Companies 1–25 of 90

Extremely Relevant

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting


Callisto Pharmaceuticals, Inc.

Callisto Pharmaceuticals, Inc., is a publicly traded biotechnology company on the American Stock Exchange (AMEX:KAL) and Frankfurt Exchange (CA4). Callisto's primary focus is the clinical development of two drugs to treat cancer, L-Annamycin for relapsed leukemia and Atiprimod for relapsed multiple myeloma (MM) and bone resorption. L-Annamycin, a drug from the anthracycline family, earlier complet...

Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigat...


Relevant

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

The Multiple Myeloma Research Consortium (MMRC)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

The Multiple Myeloma Research Foundation

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2009, approximately 20,000 adults in the United States were diagnosed with multiple myeloma and approximately 11,000 people died from the disease.

Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint i...

DACOGEN

DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and i...

Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to ...

Myeloma Canada

Multiple myeloma, a cancer of the bone marrow, is an incurable but treatable disease. The cancer starts in plasma cells, which are produced in the bone marrow. In myeloma, abnormal plasma cells, called myeloma cells, grow uncontrollably, crowding out the normal blood cells in the bone. This can bring on symptoms such as fatigue, recurrent infections and se...

Moving Mountains for Multiple Myeloma

Moving Mountains for Multiple Myeloma is supported by the MMRF, CURE Media Group and Takeda. In addition to the Mt. Fuji 2017 climb, Moving Mountains for Multiple Myeloma treks planned for 2018 include a trip to Everest Base Camp in March. Funds raised by the Moving Mountains for Multiple Myeloma endeavors will go directly to research, supporting the MMRF ...

The Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to ...

Coronado Biosciences, Inc.

Coronado Biosciences, Inc. is a private, clinical stage company that is focused on the development of therapeutic products for the treatment of cancer. Coronado has three programs; cndo102 activated NK cells for the treatment of relapsed/refractory AML, cndo101, a 4th generation doxorubicin analogue for the treatment of women with breast cancer who have the CAP17 duplication, and C1, a pan Bcl-2 ...

GNS Healthcare and The Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatme...

Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in t...

GNS Healthcare (GNS) and Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatme...

The International Myeloma Foundation

Leading myeloma experts will discuss the latest treatment paradigms, coming out of ASH that could deliver the long-term survivors of the future, in a panel discussion moderated by Dr. Durie.

The Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: University of California, San Francisco, City of Hope, Dana-Farber Cancer Institute, Emory...

Kesios Therapeutics

Kesios is developing novel therapeutics for the treatment of multiple myeloma and other cancers. KES-0001, the company’s lead drug candidate, is about to enter clinical studies as a potential treatment for multiple myeloma. The company was created to commercialise research led by Professor Guido Franzoso from the Department of Medicine at Imperial Col...

Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a) 3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 13 member institutions: University of California, San Francisco, City of Hope, Dana-Farber Cancer Institute, Emor...

International Myeloma Foundation

Video of the winning moment can be found at http://www.jeopardy.com/minisites/celebrityjeopardy/

The International Myeloma Foundation (IMF)

Institute for Myeloma and Bone Cancer Research

Probably Relevant

The International Myeloma Foundation and the Myelodysplastic Syndromes Foundation

PharmaMar USA

PharmaMar was founded in 1986, as part of the Zeltia group, with the vision of exploiting the great potential of the oceans as a source of novel medicines for improved cancer treatment. PharmaMar headquarters are located in Madrid (Spain) with additional laboratories located in Cambridge (Massachusetts). PharmaMar has become a leading company in the field of marine anticancer drugs, with six novel...


More From BioPortfolio on "Aplidin - Dexamethasone in Relapsed/Refractory Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks